Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Reports Second Quarter 2022 Financial Results
August 08, 2022 16:01 ET | FibroGen, Inc.
Completed enrollment of LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory patients with Duchenne muscular dystrophy2Q 2022 revenue of $29.8 million, growth of 22% vs. 2Q 2021Continued significant...
Straits Research Pvt Ltd
CRISPR Gene Editing Market Size is projected to reach USD 14.80 Billion by 2030, growing at a CAGR of 29.80%: Straits Research
August 01, 2022 12:40 ET | Straits Research
New York, United States, Aug. 01, 2022 (GLOBE NEWSWIRE) -- CRISPR Gene Editing, also called genome editing, modifies an organism's DNA. This method replaces, adds, or removes genetic material from...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report Second Quarter 2022 Financial Results
July 25, 2022 07:00 ET | FibroGen, Inc.
SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2022 financial results on Monday, August 8 after the market close. FibroGen will also...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Participate at William Blair Biotech Focus Conference 2022
July 01, 2022 07:00 ET | FibroGen, Inc.
SAN FRANCISCO, July 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the William...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy
June 08, 2022 07:00 ET | FibroGen, Inc.
- 73 Ambulatory DMD Patients Enrolled -- Topline Data Anticipated 2H:2023 - SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Present at Jefferies Healthcare Conference
May 26, 2022 07:00 ET | FibroGen, Inc.
SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Jefferies...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Reports First Quarter 2022 Financial Results
May 09, 2022 16:01 ET | FibroGen, Inc.
Completed enrollment in ZEPHYRUS-1 Phase 3 study of pamrevlumab in idiopathic pulmonary fibrosis1Q 2022 revenue of $60.8M, growth of 58% vs. 1Q 2021Significant roxadustat volume growth in China in...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
April 20, 2022 07:00 ET | FibroGen, Inc.
- 356 IPF Patients Enrolled - - Topline Data Anticipated Mid-2023 - SAN FRANCISCO, April 20, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient...
Logo.jpg
Antisense Therapeutics to present poster at world’s largest NMD conference
March 09, 2022 15:01 ET | Antisense Therapeutics Limited
New York, NY, March 09, 2022 (GLOBE NEWSWIRE) -- Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] will deliver a virtual presentation on its antisense drug at the Muscular...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results
February 28, 2022 16:01 ET | FibroGen, Inc.
Completed enrollment in LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer Completed enrollment in LELANTOS-1 Phase 3 study of pamrevlumab in Duchenne muscular...